You are here: Home / News & Events / News


President Signs FDA Safety and Innovation Act
FDA Safety and Innovation Act Signed—A Monumental Step Toward the Development of Safe and Effective Treatments for Millions of Americans With Rare Diseases
NORD Applauds Congress for Bipartisan Action
The FDA Safety and Innovation Act (S. 3187) offers new hope for rare disease patients and their families, NORD says.
NORD Calls Bill Passed By Senate Today Most Important Since Orphan Drug Act
NORD applauds legislation passed by the Senate and says it contains the most comprehensive improvements to public policy for rare disease therapies since 1983.
Images from the NORD 2012 Partners in Progress Celebration
View images from the NORD 2012 Partners in Progress Celebration which took place on May 15th at Union Station in Washington, DC.
NORD Forum Speaker: PDUFA V Offers Greatest Advances Since Orphan Drug Act
NORD Corporate Council Meeting stressed the importance of PDUFA V.
Boston Marathon 2012
On April 16th a group of thirteen Genzyme employees ran on behalf of NORD in the Boston Marathon.
NORD Honors Rare Disease Advocates and Innovators
NORD honored members of Congress, patient advocates, medical researchers, and companies that have brought new therapies to market on May 15, in Washington, DC.
NORD Announces New Cushing's Syndrome Patient Assistance Program
In partnership with Corcept Therapeutics Inc., NORD has established a Cushing's Syndrome Patient Assistance Program.
Alliance Seeks 6% Funding Increase for FDA
The Alliance for a Stronger FDA is requesting FY 2013 budget authority (BA) appropriations (non-user fees) for the FDA of $2.656 billion.
NORD Supports FAST Act
Introduced by Representatives Stearns and Towns, FAST is a Bill to Expedite Development of Therapies for Patients with Unmet Medical Needs

Copyright ©2014 NORD - National Organization for Rare Disorders, Inc. All rights reserved.